Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06524414 · ClinicalTrials.gov registry record · Phase 2
A Study to Learn About How a New Pneumococcal Vaccine Works in Infants
A Phase 2 study of Pneumococcal Disease, sponsored by Pfizer.
- Active
- Registry status
- Phase 2
- Development phase
- 605
- Enrollment target
- 20
- Study locations
NCT06524414 is a Phase 2 study of Pneumococcal Disease that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 605 participants, above the 385-participant average among 3 other Pneumococcal Disease trials with a reported enrollment target (57% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT06524414, a Phase 2 study of Pneumococcal Disease, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 605 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs in infants when compared to the pneumococcal vaccines that are currently in use, 20vPnC (Prevnar 20®) or another licensed pneumococcal vaccine. To ensure that the new vaccine (PG4) stays stable, it is placed in a liquid mixture of sterile water and other substances (a solution). This study will also test if there is a difference in the safety and immune effects of the new pneumococcal vaccine when it is one type of solution compared to when it is in a different type of solution. The immune response is how the body's cells; tissues and organs work together to protect the body from infection. Blood samples will be used to measure the amount of antibodies produced after the vaccination. Antibodies are proteins that protect you when an unwanted germ enters the body. This will help understand how well the new pneumococcal vaccine works. This vaccine can possibly provide protection against pneumococcal disease. Pneumococcal disease includes a variety of infections caused by a specific germ, Streptococcus pneumoniae. This study is seeking participants who are: * male or female infants who are 2 months of age, * infants born at 36 weeks (about 8 and a half months) of pregnancy or later; and, * said to be healthy by the study doctor There are four groups in this study. All participants will be assigned to one of the four groups. All study vaccines will be given as a single shot into the left thigh muscle. Participants in the three groups will have 3 blood samples collected during the 1 and a half years they are in the study. The first 400 participants who enter the study will be assigned to either Group 1 or Group 2. Half the participants in Group 1 and half the participants in Group 2 will receive 4 doses at 2, 4, 6, and 12 to 15 months of age of PG4 mixed in the first solution. The other half of the participants in Gro
Conditions Studied
Interventions
- BIOLOGICAL PG4
- BIOLOGICAL 20-valent pneumococcal conjugate vaccine (20vPnC)
- BIOLOGICAL 15-valent pneumococcal conjugate vaccine (PCV15)
Study Locations (20)
California
- Los Ninos Children's Medical Clinic - La Puente
- Stanford University Medical Center - Palo Alto
- Los Ninos Children's Medical Clinic - West Covina
Kentucky
- Kentucky Pediatric/ Adult Research - Bardstown
- All Children Pediatrics - Louisville
- Bluegrass Clinical Research, Inc. - Louisville
Louisiana
- LSUHSC Clinical Trials Office - Shreveport
- Louisiana State University Health Sciences Shreveport - Shreveport
- Ochsner/LSU Health Ambulatory Care Center - Shreveport
Arkansas
- Northwest Arkansas Pediatric Clinic - Fayetteville
- The Children's Clinic - Jonesboro
Maryland
- University of Maryland - Baltimore
- UMB/CVD - Frederick
District of Columbia
- Velocity Clinical Research, Washington DC - Washington D.C.
Florida
- Riveldi Biomedical Research and Associates - Miami - Miami Lakes
Idaho
- Clinical Research Prime - Idaho Falls
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 605 participants |
| Start Date | 2024-07-25 |
| Est. Completion | 2027-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06524414
The ClinicalTrials.gov registry entry for NCT06524414 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 605 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 385-participant average among 3 other Pneumococcal Disease trials with a reported enrollment target (57% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pneumococcal Disease appearing as the primary indexed condition, and to 3 interventions - of which PG4 is the first listed.
NCT06524414 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Kentucky, Louisiana.
Frequently Asked Questions
What is clinical trial NCT06524414 about?
NCT06524414 is a clinical study titled "A Study to Learn About How a New Pneumococcal Vaccine Works in Infants". The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs in infants when compared to the pneumococcal vaccines that are currently in use, 20vPnC (Prevnar 20®) or another licensed pneumococcal vaccine. To e...
What is the current status of trial NCT06524414?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 605 participants. The study started on 2024-07-25. Estimated completion is 2027-05-01.
What conditions does trial NCT06524414 study?
This clinical trial studies the following conditions: Pneumococcal Disease.
What interventions are being tested in trial NCT06524414?
The interventions under investigation include: PG4 (BIOLOGICAL), 20-valent pneumococcal conjugate vaccine (20vPnC) (BIOLOGICAL), 15-valent pneumococcal conjugate vaccine (PCV15) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06524414?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06524414 being conducted?
This trial has 20 study locations across Arkansas, California, District of Columbia, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumococcal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About How a New Pneumococcal Vaccine Works in Children
COMPLETED · Phase 2
-
A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults
ACTIVE NOT RECRUITING · Phase 1
-
Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.